BerGenBio

Selective AXL inhibitors

Home  /  Media Centre  /  News

First Axl inhibitor enters clinical trials (2013)

Share This Post

Sheridan C. Nat Biotechnol. 2013 Sep;31(9):775-6. doi: 10.1038/nbt0913-775a.
Nature Biotechnology covered the initiation of BerGenBio’s phase 1 trial with BGB324.
Please click here for more information.

Share This Post

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.